Comparison Chart Verastem, Inc.

Stocks

VSTM

US92337C2035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 00:00:00 01/08/2026 +04			5-day change	1st Jan Change
5.800 ^USD	-4.92%		-4.13%	-24.87%

07-29	Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer	CI
07-23	Verastem Oncology Doses First Patient in Target-D 202 Phase 2 Registration-Directed Trial of Vs-7375 for Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	VERASTEM, INC.	Bio Therapeutic Drugs	-4.92%	-4.13%	-24.87%	-6.00%	-85.04%	510M